A. Mocroft, B. Ledergerber, C. Katlama, O. Kirk, P. Reiss et al., EuroSIDA study group: Decline in the AIDS and death rates in the EuroSIDA study: an observational study, Lancet, issue.9377, pp.36222-36251, 2003.

C. Delaugerre, J. Ghosn, J. Lacombe, G. Pialoux, L. Cuzin et al., Trend over calendar time in virological failure in HIV-infected patients treated for at least six months with combined antiretroviral therapy in France (FHDH ANRS CO04)InPaper presented at: 6 th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, p.104, 2011.

P. Morlat, Recommandations du groupe d'experts 2013 Prise en charge médicale des personnes vivant avec le VIH

M. French, M. King, J. Tschampa, B. Da-silva, and A. Landay, T Cells, The Journal of Infectious Diseases, vol.200, issue.8, pp.2001212-1215, 2009.
DOI : 10.1086/605890

J. Neuhaus, D. Jacobs, . Jr, J. Baker, A. Calmy et al., Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection, The Journal of Infectious Diseases, vol.201, issue.12, pp.2011788-1795, 2010.
DOI : 10.1086/652749

M. Mavigner, P. Delobel, M. Cazabat, M. Dubois, L. 'faqihi-olive et al., HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy, PLoS ONE, vol.12, issue.10, p.7658, 2009.
DOI : 10.1371/journal.pone.0007658.s004

P. Hunt, J. Martin, E. Sinclair, L. Epling, J. Teague et al., Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy, Journal of Infectious Diseases, vol.203, issue.10, pp.2031474-1483, 2011.
DOI : 10.1093/infdis/jir060

M. Petrara, A. Cattelan, M. Zanchetta, L. Sasset, R. Freguja et al., Epstein-Barr Virus load and immune activation in Human Immunodeficiency Virus type 1-infected patients, Journal of Clinical Virology, vol.53, issue.3, pp.195-200
DOI : 10.1016/j.jcv.2011.12.013

H. Lane, Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation, Top HIV Med, vol.18, issue.1, pp.2-6, 2010.

V. Terzieva, Regulatory T Cells and HIV-1 Infection, Viral Immunology, vol.21, issue.3, pp.285-291, 2008.
DOI : 10.1089/vim.2008.0006

M. Savès, F. Raffi, J. Capeau, W. Rozenbaum, J. Ragnaud et al., Antiprotéases Cohorte (APROCO) Study Group: Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy, Clin Infect Dis, issue.10, pp.341396-1405, 2002.

T. Brown and R. Qaqish, Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review, AIDS, vol.20, issue.17, pp.2165-2174, 2006.
DOI : 10.1097/QAD.0b013e32801022eb

S. Lang, M. Mary-krause, L. Cotte, J. Gilquin, M. Partisani et al., French Hospital Database on HIV-ANRS CO4: Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population, AIDS, vol.2010, issue.8, pp.241228-1230

E. Lanoy, J. Spano, F. Bonnet, M. Guiguet, F. Boué et al., The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study, International Journal of Cancer, vol.45, issue.2, pp.467-475, 2011.
DOI : 10.1002/ijc.25903

G. Guaraldi, G. Orlando, S. Zona, M. Menozzi, F. Carli et al., Premature age-related comorbidities among HIVinfected persons compared with the general population, Clin Infect Dis, issue.11, pp.531120-1126, 2011.

S. Lang, M. Mary-krause, A. Simon, M. Partisani, J. Gilquin et al., French Hospital Database on HIV (FHDH)?ANRS CO4: HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals, Clin Infect Dis, vol.2012, issue.554, pp.600-607

S. Lang, M. Mary-krause, L. Cotte, J. Gilquin, M. Partisani et al., Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus???Infected Patients<subtitle>A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4</subtitle><alt-title>Antiretroviral Drugs, Risk of MI, and HIV</alt-title>, Archives of Internal Medicine, vol.170, issue.14, pp.1228-1238, 2010.
DOI : 10.1001/archinternmed.2010.197

T. Brown, K. Tassiopoulos, R. Bosch, C. Shikuma, and G. Mccomsey, Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy, Diabetes Care, vol.33, issue.10, pp.2244-2249, 2010.
DOI : 10.2337/dc10-0633

A. Pradhan, J. Manson, N. Rifai, J. Buring, and P. Ridker, C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus, JAMA, vol.286, issue.3, pp.327-334, 2001.
DOI : 10.1001/jama.286.3.327

M. Clearfield, C-reactive protein: a new risk assessment tool for cardiovascular disease, J Am Osteopath Assoc, vol.105, issue.9, pp.409-416, 2005.

H. Schuett, M. Luchtefeld, C. Grothusen, K. Grote, and B. Schieffer, How much is too much? Interleukin-6 and its signalling in atherosclerosis, Thrombosis and Haemostasis, vol.102, issue.2, pp.215-222, 2009.
DOI : 10.1160/TH09-05-0297

L. Kuller, R. Tracy, W. Belloso, D. Wit, S. Drummond et al., Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection, PLoS Medicine, vol.180, issue.10, p.203, 2008.
DOI : 10.1371/journal.pmed.0050203.sd002

P. Hunt, E. Sinclair, B. Rodriguez, C. Shive, B. Clagett et al., Gut epithelial barrier dysfunction, inflammation and coagulation predict higher mortality during treated HIV/AIDS.InPaper presented at: 19 th Conference on Retroviruses and Opportunistic Infections, Abstract, vol.278, 2012.

D. Luca, A. De-gaetano, D. Colafigli, M. Cozzi-lepri, A. et al., The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case?control study, BMC Infect Dis, vol.2013, issue.131, p.414

A. Trenorio, Z. Yu, R. Bosch, S. Deeks, R. Benigno et al., AIDS Clinical Trials Group: Soluble markers of inflammation and coagulation, but not T-cell activation predict non-AIDS defining events during suppressive antiretroviral therapy Abstract 790, 20 th Conference on Retroviruses and Opportunistic Infections, 2013.

E. Martínez, D. 'albuquerque, P. Llibre, J. Gutierrez, F. Podzamczer et al., SPIRAL Trial Group: Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir, AIDS, vol.2012, issue.18, pp.262315-2326

K. Smith, P. Patel, D. Fine, N. Bellos, L. Sloan et al., Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment, AIDS, vol.23, issue.12, pp.1547-1556, 2009.
DOI : 10.1097/QAD.0b013e32832cbcc2

G. Mccomsey, D. Kitch, E. Daar, C. Tierney, N. Jahed et al., Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir, AIDS, vol.26, issue.11, pp.261371-1385
DOI : 10.1097/QAD.0b013e328354f4fb

N. Funderburg, M. Kalinowska, J. Eason, J. Goodrich, J. Heera et al., Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients, PLoS ONE, vol.5, issue.10, p.13188, 2010.
DOI : 10.1371/journal.pone.0013188.s002

D. Wohl, G. Arnoczy, C. Fichtenbaum, T. Campbell, B. Taiwo et al., Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study, Antiviral Therapy, vol.19, issue.2, 2013.
DOI : 10.3851/IMP2681

S. Deeks, R. Tracy, and D. Douek, Systemic Effects of Inflammation on Health during Chronic HIV Infection, Immunity, vol.39, issue.4, pp.633-645
DOI : 10.1016/j.immuni.2013.10.001

S. Pine, L. Mechanic, L. Enewold, A. Chaturvedi, H. Katki et al., Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer, JNCI Journal of the National Cancer Institute, vol.103, issue.14, pp.1112-1122, 2011.
DOI : 10.1093/jnci/djr216

D. Boulware, K. Hullsiek, C. Puronen, A. Rupert, J. Baker et al., INSIGHT Study Group: Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of http antiretroviral therapy (ART) are associated with increased risk of AIDS or death, J Infect Dis, vol.14122, issue.11, pp.2031637-1646, 2011.

N. Sandler, H. Wand, A. Roque, M. Law, M. Nason et al., Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection, Journal of Infectious Diseases, vol.203, issue.6, pp.780-790, 2011.
DOI : 10.1093/infdis/jiq118

E. Cassol, S. Malfeld, P. Mahasha, S. Van-der-merwe, S. Cassol et al., Persistent Microbial Translocation and Immune Activation in HIV???1???Infected South Africans Receiving Combination Antiretroviral Therapy, The Journal of Infectious Diseases, vol.202, issue.5, pp.723-733, 2010.
DOI : 10.1086/655229

A. Kamat, V. Misra, E. Cassol, P. Ancuta, Z. Yan et al., A Plasma Biomarker Signature of Immune Activation in HIV Patients on Antiretroviral Therapy, PLoS ONE, vol.118, issue.2, p.30881
DOI : 10.1371/journal.pone.0030881.s003

N. Sandler and D. Douek, Microbial translocation in HIV infection: causes, consequences and treatment opportunities, Nature Reviews Microbiology, vol.10, issue.9, pp.655-666
DOI : 10.1038/nrmicro2848

D. 'ettorre, G. Paiardini, M. Zaffiri, L. Andreotti, M. Ceccarelli et al., HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS, Curr HIV Res, vol.2011, issue.93, pp.148-153

B. Taiwo, R. Matining, L. Zheng, M. Lederman, C. Rinaldo et al., Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy, Journal of Antimicrobial Chemotherapy, vol.68, issue.8, pp.681857-1861
DOI : 10.1093/jac/dkt120

M. Lederman, L. Calabrese, N. Funderburg, B. Clagett, K. Medvik et al., Immunologic Failure Despite Suppressive Antiretroviral Therapy Is Related to Activation and Turnover of Memory CD4 Cells, Journal of Infectious Diseases, vol.204, issue.8, pp.2041217-1226, 2011.
DOI : 10.1093/infdis/jir507

P. Hunt, J. Brenchley, E. Sinclair, J. Mccune, R. M. Page-shafer et al., T Cell Count in HIV???Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy, The Journal of Infectious Diseases, vol.197, issue.1, pp.126-133, 2008.
DOI : 10.1086/524143

B. Moser, M. Loetscher, L. Piali, and P. Loetscher, Lymphocyte Responses to Chemokines, International Reviews of Immunology, vol.4, issue.3-4, pp.3-4323, 1998.
DOI : 10.1083/jcb.134.1.255

L. Juompan, K. Hutchinson, D. Montefiori, S. Nidtha, and F. Villinger, Analysis of the Immune Responses in Chimpanzees Infected with HIV Type 1 Isolates, AIDS Research and Human Retroviruses, vol.24, issue.4, pp.573-586, 2008.
DOI : 10.1089/aid.2007.0182

A. Liovat, R. Lécuroux, C. , J. B. Girault, I. Petitjean et al., Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection, PLoS ONE, vol.7, issue.10, p.46143
DOI : 10.1371/journal.pone.0046143.s007

A. Edén, L. Andersson, O. Andersson, L. Flamholc, F. Josephson et al., Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Na??ve HIV-1???Infected Patients, AIDS Research and Human Retroviruses, vol.26, issue.5, pp.533-540, 2010.
DOI : 10.1089/aid.2009.0177

C. Katlama, S. Deeks, B. Autran, J. Martinez-picado, J. Van-lunzen et al., Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs, The Lancet, vol.381, issue.9883, pp.3812109-2117
DOI : 10.1016/S0140-6736(13)60104-X